EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Benefits of reducing duration of endoscopic duodenal-jejunal bypass liner implantation to nine months in treatment of diabesity

Robert E J Ryder, Mahi Yadagiri, Caroline Day, Wyn Burbridge, Susan P Irwin, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Melanie Wyres, Melissa Cull, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta

British Journal of Diabetes · 2024-10-24

DOI: 10.15277/bjd.2024.460 ↗
AbstractBibliografische Angaben

Abstract

Aims: To assess the safety and efficacy of duodenal-jejunal bypass liner (DJBL) implantation for 9 months or 12 months in patients with obesity and sub-optomally controlled type 2 diabetes (T2DM). Methods: Over 4.25 years DJBLs were implanted in 90 adult patients with obesity and sub-optimally controlled T2DM at a single centre in England. The liners remained in situ for up to 12 months and outcomes were monitored in a registry. Results: Of the 90 patients (BMI 41.5±7.1kg/m2, HbA1c 79.3±20 mmol/mol), 53% were insulin-treated. During DJBL treatment, there was no difference between the mean±SD fall in HbA1c at 9 months (20.5±18.8mmol/mol) vs. 12 months (20.5±19.4mmol/mol) (p=0.95). The mean±SD weight loss at 9 months (13.8±7.7kg) was 1.6±3.6kg less than that at 12 months (15.4±8.4kg) (p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →